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Abstract 
Background: It has been shown that visceral fat accumulation is associated with autonomic dysfunction, though the 
precise mechanism remains unclear. A recent basic study found that leptin can directly modulate autonomic function 
through the dorsomedial hypothalamus in relation to obesity. Here, we investigated the mutual relationships among 
plasma leptin, visceral fat accumulation, and cardiac autonomic dysfunction in patients with type 2 diabetes.
Methods: This cross‑sectional study included 100 diabetic patients, and 100 age‑ and gender‑matched non‑diabetic 
patients with cardiovascular risk factors. Plasma leptin and soluble leptin receptor levels, visceral fat area (VFA), and 
heart rate variability (HRV) were determined in addition to classical cardiovascular risk factors.
Results: In the type 2 diabetic patients, VFA was significantly (p < 0.05) and inversely associated with HRV parameters 
(SDNN: r = −0.243; SDANN5: r = −0.238), while the plasma level of leptin, but not soluble leptin receptor, was also 
significantly (p < 0.05) and inversely associated with HRV parameters (SDNN: r = −0.243; SDANN5: r = −0.231). Mul‑
tiple regression analysis showed that plasma leptin was significantly associated with SDNN and SDANN5 independ‑
ent of other factors, including age, gender, presence of hypertension and dyslipidemia, duration of diabetes, HbA1c, 
and eGFR. Furthermore, the relationship of leptin with SDNN and SDANN5 (β = −0.279 and −0.254, respectively) 
remained significant (p < 0.05) after adjustment for VFA. In patients without diabetes, no significant associations were 
observed between leptin and any of the HRV parameters.
Conclusions: Hyperleptinemia may be involved in cardiac autonomic dysfunction in patients with type 2 diabetes 
and visceral obesity.
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Background
The prevalence of obesity has been increasing through-
out the world over the past several decades to become a 
global health problem [1]. Excess visceral fat accumula-
tion accompanied by obesity contributes to development 
of hypertension, diabetes, dyslipidemia, and cardio-
vascular events [2, 3]. Adiposity and cardiac autonomic 
dysfunction are closely associated [4], which may be 
involved in a higher incidence of cardiovascular events in 
obese individuals [5, 6]. However, the underlying mecha-
nisms for cardiac autonomic dysfunction related to obe-
sity remain unclear.
Leptin, a 16-kDa peptide hormone mainly derived 
from adipose tissue, suppresses appetite and increases 
energy expenditure via hypothalamic neurons expressing 
the receptor for leptin (Ob-R) [7, 8]. In clinical settings, 
plasma leptin concentrations have found to be strongly 
and positively correlated to adiposity [9–11], suggesting 
that high leptin levels lose their ability to restrain feeding 
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and fat accumulation in obesity. Of importance, a recent 
study clearly showed that hyperleptinemia, a result of 
obesity, directly modulated blood pressure and heart rate 
by acting on the dorsomedial hypothalamus expressing 
Ob-R in obese mice, probably via the sympathetic nerv-
ous system [12].
These basic findings led us to examine whether plasma 
leptin contributes to the pathophysiology of autonomic 
dysfunction in obesity in humans. Measuring heart rate 
variability (HRV) using standard electrocardiographic 
monitoring is a practical way to assess impaired auto-
nomic nervous system in clinical settings [13]. Reduced 
HRV predicts all-cause mortality and cardiovascular 
events not only in community-based population [5, 
6], patients with myocardial infarction [14], and in dia-
betic patients [15–17]. Potential mechanisms for these 
associations include higher corrected QT prolongation, 
low exercise capacity, higher levels of inflammatory bio-
marker, and deregulation of progenitor cells [18–20]. 
Thus far, no reports examining the associations among 
adiposity, plasma leptin, and HRV in patients with type 
2 diabetes have been presented. In the present study, we 
examined the mutual relationships among plasma leptin, 
HRV, and visceral fat volume in 100 patients with diabe-
tes, as well as 100 age- and gender-matched non-diabetic 
patients with cardiovascular risk factors.
Methods
Study design and participants
This cross-sectional study included 100 patients with type 
2 diabetes, and 100 age- and gender-matched patients 
without diabetes who participated in the Hyogo Sleep 
Cardio-Autonomic Atherosclerosis (HSCAA) Study, 
which was designed to examine the impacts of sleep, 
cardiac autonomic dysfunction, and subclinical athero-
sclerosis on cardiovascular events. All patients agreed to 
participate in the study by providing written informed 
consent and the study was approved by the Ethics Com-
mittee of Hyogo College of Medicine (approval No. 948). 
From the cohort, initial 100 sequential diabetic patients 
were included, and corresponding age- and gender-
matched non-diabetic patients were sequentially selected. 
Details of the cohort appear elsewhere [21], and classical 
cardiovascular risk factors and diabetes were evaluated 
as described in that publication. In diabetic groups, use 
of anti-diabetic agents included sulfonylureas (n  =  30), 
metformin (n  =  35), pioglitazone (n  =  11), dipeptidyl 
peptidase 4 (DPP4) inhibitors (n = 33), and α-glucosidase 
inhibitors (n  =  9), glucagon like peptide 1 (GLP1) ana-
logues (n = 2), and insulins (n = 19). Past history of car-
diovascular disease (CVD) was defined as the presence of 
coronary artery disease (medical history of myocardial 
infarction or revascularization), cerebrovascular disease, 
or peripheral arterial disease (PAD). Diabetic neuropathy 
was defined as the presence of two or more of the follow-
ing: neuropathic symptoms, decreased distal sensation, 
and unequivocally decreased or absent ankle reflexes 
[22]. Serum creatinine was measured using the enzymatic 
method. Estimated glomerular filtration rate (eGFR) in 
each patient was calculated using an equation for Japanese 
subjects, as previously described [23]. This cross-sectional 
study excluded participants with chronic kidney disease 
(CKD), defined as eGFR less than 30 ml/min/1.73 m2. The 
level of urinary albumin excretion (UAE) was measured in 
24-h urine specimens by immunoturbidimetry. UAE <30, 
30–300, and >300 mg/day was defined as normo-, micro-, 
and macro-albuminuria, respectively.
Cardiac autonomic nervous function
To evaluate cardiac autonomic function, HRV was deter-
mined using an Active Tracer (AC-301A, Arm Elec-
tronics, Tokyo, Japan), as previously described [24]. 
According to the recommendations for clinical use of 
HRV [13], the standard deviation of the NN(RR) interval 
(SDNN) and standard deviation of the average NN(RR) 
intervals for each 5-min (SDANN5) period were calcu-
lated. SDNN was considered to reflect all cyclic com-
ponents responsible for variability in heart rate, while 
SDANN5 was used to represent change in heart rate due 
to cycles longer than 5 min [13].
Plasma leptin and soluble leptin receptor
Blood samples were obtained essentially in the morning 
after an overnight fast during measurement of HRV and 
then quickly centrifuged to obtain plasma. Plasma leptin 
and soluble Ob-R (sOb-R) levels were measured using an 
enzyme-linked immunosorbent assay kit (R&D Systems, 
Inc., Minneapolis, MN, USA), as previously described 
[25]. The intra- and inter-assay coefficients of variation 
for leptin were 3.2 and 4.9 %, respectively, and those for 
sOb-R were 3.5 and 6.7 %, respectively.
Measurement of visceral and subcutaneous fat area
Using abdominal computed tomography (SOMATOM 
Definition, Siemens Medical Solutions, Forchheim, Ger-
many), we acquired a single 10-mm slice at the level of 
the umbilicus. Visceral fat area (VFA) and subcutaneous 
fat area (SFA) values were calculated with a Ziostation 
workstation (Ziosoft Inc., Tokyo, Japan), as previously 
described [26].
Statistical analysis
For analysis, HRV parameters (SDNN, SDANN5), and 
plasma leptin and sOb-R levels were logarithm-trans-
formed (log) to achieve normal distribution. To compare 
variables between patients with and without diabetes, a 
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non-repeated t test (continuous variables with normal dis-
tribution) and Chi square test (for categorical variables) 
were utilized. We performed simple and multiple regres-
sion analyses to evaluate the relationships between HRV 
parameters and various clinical parameters, including 
plasma leptin or sOb-R, and VFA. In multiple regression 
analysis, HRV parameters were set as a dependent vari-
ables, and VFA and plasma leptin levels were set as inde-
pendent variables after adjusting for age, gender, eGFR, 
HbA1c levels, duration of diabetes (in affected patients), 
and presence of hypertension and dyslipidemia. All sta-
tistical analyses were performed by using the Statistical 
Package for the Social Sciences software (PASW Statistics 
version 18.0). All reported p values are 2-tailed and were 
considered statistically significant at a level <0.05.
Results
Clinical characteristics of subjects with and 
without diabetes
The subject characteristics are shown in Table  1. Those 
with diabetes exhibited significantly higher body mass 
index (BMI), eGFR, fasting plasma glucose (FPG), 
HbA1c, VFA, and SFA values. The prevalence of hyper-
tension and dyslipidemia tended to be higher in diabetic 
than non-diabetic patients, while plasma leptin and 
sOb-R levels, and HRV parameters were not significantly 
different between the groups.
Associations of VFA, SFA, plasma leptin, and sOb‑R levels 
with HRV parameters
Table 2 shows the correlation coefficients between VFA, 
SFA, plasma leptin and sOb-R levels, and HRV param-
eters. VFA, but not SFA, was significantly and inversely 
associated with HRV parameters in patients with diabe-
tes (Fig.  1a, b; Table  2). In contrast, such relationships 
were not observed in the non-diabetic patients (Table 2). 
Plasma leptin level was significantly and inversely asso-
ciated with SDNN and SDANN5 in diabetic patients 
(Fig.  1c, d; Table  2), but not in the non-diabetic group 
(Table 2). Plasma sOb-R level was not significantly asso-
ciated with HRV parameters in either group. On the 
other hand, plasma leptin levels were significantly and 
positively associated with VFA (r  =  0.417, p  <  0.001, 
r  =  0.262; p  =  0.008) and SFA (r  =  0.732, p  <  0.001, 
r =  0.693; p  <  0.001) in both the diabetic and non-dia-
betic subjects. Also, plasma sOb-R level showed a ten-
dency to be associated with VFA (r = −0.181, p = 0.072, 
r = −0.190; p = 0.058), but not with SFA, in both groups.
Associations of plasma leptin levels with HRV parameters 
in patients with or without diabetic neuropathy
Plasma leptin (0.83  ±  0.41 vs. 0.79  ±  0.42, p = 0.610), 
SDNN (2.00   ±   0.13 vs. 2.04   ±   0.14, p =  0.165), and 
SDANN5 (1.96  ±  0.13 vs. 1.99  ±  0.14, p = 0.183) were 
not significantly different when compared between dia-
betic patients with (n =  48) and without (n =  52) neu-
ropathy. In patients with diabetic neuropathy, leptin 
was significantly associated with SDNN (r  =  −0.323, 
p  =  0.02) or SDANN5 (r  =  −0.338, p  =  0.014). On 
the other hand, in patients without diabetic neuropa-
thy, leptin was not significantly associated with SDNN 
(r  =  −0.137, p  =  0.355) or SDANN5 (r  =  −0.092, 
p = 0.534).
Plasma leptin level is associated with HRV parameters 
independent of clinical factors and adiposity in diabetic 
patients
To further examine whether the relationship of plasma 
leptin with cardiac autonomic dysfunction in diabetic 
patients was independent of the other confounding 
factors, multiple regression analyses were performed 
(Table  3). In basic model 1, which included age, male 
gender, eGFR, HbA1c, presence of hypertension and dys-
lipidemia, and duration of diabetes as covariates, dura-
tion of diabetes was the sole significant factor associated 
with SDNN and SDANN5. When VFA was included as 
an additional covariate (model 2), both duration of dia-
betes and VFA were significantly associated with HRV 
parameters. In model 3 (addition of plasma leptin to 
model 1 covariates), plasma leptin remained significantly 
associated with SDNN and SDANN5. When both VFA 
and plasma leptin were added to the model 1 covari-
ates (model 4), plasma leptin, but not VFA, exhibited 
significant and independent associations with SDNN 
and SDANN5. When BMI was included as an additional 
covariate to model 4, plasma leptin, but neither VFA nor 
BMI, remained significantly associated with SDNN and 
SDANN5 (data no shown). When use of any of an anti-
diabetic agent (sulfonylurea, metformin, pioglitazone, 
DPP4 inhibitor, α-glucosidase inhibitor, GLP1 analogue, 
or insulin) was included as an additional covariate to 
model 4, plasma leptin remained significantly associ-
ated with SDNN (data no shown). Among the agents, 
only use of insulin was independently associated with 
SDNN (β  =  −0.224, p  =  0.034) together with plasma 
leptin (β = −0.256, p = 0.042) and duration of diabetes 
(β = −0.223, p = 0.041). Finally, when presence of previ-
ous CVD events was included as an additional covariate 
to model 4, plasma leptin remained significantly asso-
ciated with SDNN (β = −0.275, p =  0.033) and tended 
to associated with SDANN5 (β  =  −0.243, p  =  0.061). 
When multiple regression analyses were re-performed in 
79 non-CVD patients (model 4), both plasma leptin and 
duration of diabetes showed tendency to associate with 
SDNN (β = −0.280, p = 0.062; β = −0.233, p = 0.051, 
respectively) and SDANN5 (β  =  −0.281, p  =  0.066; 
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Table 1 Clinical characteristics of patients with and without diabetes
Data are expressed as the mean ± standard deviation and number for dichotomous variables
Plasma leptin and sOb-R levels, and all HRV parameters (CVRR, SDNN, SDANN5, HRV triangular index) were natural logarithm-transformed (log) to achieve a normal 
distribution. P values shown are for comparisons of the means of 2 groups (unrepeated t-test) or percentages (Chi square test)
BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, DM diabetes mellitus, DPP4 dipeptidyl 
peptidase 4, GLP1 glucagon-like peptide 1, VFA visceral fat area, SFA subcutaneous fat area, normo- normal albuminuria, micro- microalbuminuria, macro- macro-
albuminuria, sOb-R soluble leptin receptor, SDNN standard deviation of NN(RR) interval, SDANN5 standard deviation of average NN(RR) intervals for each 5-min period
Variables DM (n = 100) NDM (n = 100) p value
Age (years) 62.9 ± 9.3 62.9 ± 9.5 0.988
Gender (male/female) 62/38 62/38
BMI (kg/m2) 26.1 ± 4.7 23.3 ± 3.3 <0.001
Hypertension (yes/no) 71/29 59/41 0.075
Dyslipidemia (yes/no) 72/28 59/41 0.053
Past CVD events (yes/no) 21/79 17/83 0.762
Smoker (yes/no) 32/68 20/80 0.053
eGFR (ml/min/1.73 m2) 85.0 ± 24.9 76.4 ± 16.0 0.004
FPG (mg/dl) 132.9 ± 36.7 94.5 ± 10.4 <0.001
HbA1c (%) 7.2 ± 1.3 5.3 ± 0.4 <0.001
Duration of DM (years) 10.4 ± 9.0
Diabetic neuropathy (yes/no) 48/52
Diabetic nephropathy (normo‑/micro‑/macro‑) 78/19/3
Anti‑diabetes agents
 Sulfonylurea (%) 30
 Metformin (%) 35
 Pioglitazone (%) 11
 DPP4 inhibitor (%) 33
 α‑glucosidase inhibitor (%) 9
 GLP1 analogue (%) 2
 Insulin (%) 19
VFA (cm2) 105.2 ± 47.9 78.3 ± 44.6 <0.001
SFA (cm2) 165.3 ± 93.1 129.8 ± 74.1 0.003
log (leptin) (ng/mL) 0.81 ± 0.41 0.73 ± 0.41 0.166
log (sOb‑R) (ng/mL) 1.35 ± 0.13 1.33 ± 0.14 0.214
log (SDNN) (ms) 2.02 ± 0.14 2.05 ± 0.12 0.184
log (SDANN5) (ms) 1.97 ± 0.14 1.99 ± 0.13 0.309
Table 2 Associations of VFA, SFA, plasma leptin, and sOb-R levels with HRV parameters
HRV parameters (SDNN, SDANN5), and plasma leptin and sOb-R levels were natural logarithm-transformed (log) to achieve a normal distribution
HRV heart rate variability, SDNN standard deviation of NN(RR) interval, SDANN5 standard deviation of average NN(RR) intervals for each 5-min period, VFA visceral fat 
area, SFA subcutaneous fat area, sOb-R soluble leptin receptor
DM (n = 100) NDM (n = 100)
log (SDNN) log (SDANN5) log (SDNN) log (SDANN5)
r p r p r p r p
VFA −0.243 0.015 −0.238 0.017 −0.039 0.699 −0.001 0.993
SFA −0.116 0.252 −0.113 0.261 0.053 0.599 0.078 0.438
log (leptin) −0.243 0.015 −0.231 0.021 −0.020 0.842 0.005 0.959
log (sOb‑R) −0.061 0.545 −0.040 0.694 0.106 0.296 0.103 0.307
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β = −0.207, p = 0.087, respectively). In contrast, neither 
VFA nor plasma leptin was independently associated 
with HRV parameters in the non-diabetic patients (data 
not shown).
Discussion
Plasma leptin in obesity and diabetes
Plasma leptin levels are closely associated with adiposity 
[9–11], and its level correlated with increased metabolic 
Fig. 1 Associations of HRV parameters (a, c SDNN, b, d SDANN5) with visceral fat area (a, b) and plasma leptin levels (c, d) in patients with type 2 
diabetes
Table 3 Multiple regression analysis of factors associated with HRV parameters in 100 patients with diabetes
eGFR estimated glomerular filtration rate, DM diabetes mellitus, VFA visceral fat area, SDNN standard deviation of NN(RR) interval, SDANN5 standard deviation of 
average NN(RR) intervals for each 5-min period, HRV heart rate variability
† Denotes p value <0.05
Variables log (SDNN) log (SDANN5)
Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4
Age −0.187 −0.170 −0.215 −0.204 −0.166 −0.149 −0.193 −0.180
Gender (female = 0, male = 1) −0.040 0.005 −0.190 −0.146 −0.038 0.006 −0.177 −0.132
Hypertension (absence = 0, presence = 1) −0.103 −0.040 −0.023 −0.010 −0.119 −0.059 −0.044 −0.031
Dyslipidemia (absence = 0, presence = 1) −0.136 −0.127 −0.110 −0.111 −0.141 −0.133 −0.117 −0.118
eGFR −0.140 −0.118 −0.152 −0.141 −0.106 −0.085 −0.118 −0.106
HbA1c −0.117 −0.071 −0.096 −0.080 −0.096 −0.051 −0.076 −0.059
Duration of DM −0.250† −0.286† −0.264† −0.277† −0.244† −0.278† −0.257† −0.270†
VFA −0.233† −0.096 −0.227† −0.101
log (leptin) −0.333† −0.279† −0.312† −0.254†
Adjusted r2 0.100 0.140 0.179 0.176 0.089 0.126 0.156 0.153
p value 0.018 0.005 0.001 0.001 0.028 0.008 0.002 0.004
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syndrome components [27]. Plasma leptin level in dia-
betes is rather controversial; one recent study does not 
observe any significant difference between diabetic and 
non-diabetic subjects [28], others reported significant 
lower level in type 1 diabetic subjects [29] and type 2 dia-
betics with similar adiposity [30]. In our current study, 
plasma leptin level was comparable between diabetic and 
non-diabetic patients even though BMI, VFA and SFA 
are significant higher in diabetes. These controversial 
findings may be due to the status of insulin resistance and 
deficiency since plasma leptin level may be modified by 
insulin or C-peptide [29, 31].
Leptin and autonomic function
Recent study had shown that leptin may directly modu-
late autonomic function in obese mouse [12]. However, 
limited studies have shown an association of plasma 
leptin level with HRV in humans. In healthy subjects or 
police officers, short term frequency-domains of HRV are 
associated with plasma leptin [32, 33]. The relationships 
of time-domains of HRV, markers of overall autonomic 
function, with plasma leptin are only shown in male 
school teachers [34] and males with acute myocardial 
infarction [35]. Only a limited study showed significant 
association of HRV parameters with adiponectin/leptin 
ratio in diabetic subjects [36]. The present study is the 
first to show its relationship in type 2 diabetic patients, 
with the relationship fully adjusted for clinical param-
eters including quantitatively determined visceral adipos-
ity. Its association was specific to diabetic patients since 
no significant associations were observed between leptin 
and any of the HRV parameters in non-diabetic patients.
Potential mechanisms why association between plasma 
leptin and HRV observed in diabetic patients only
Although it is not clear at present why the independ-
ent relationship between plasma leptin and HRV was 
observed in diabetic patients only, the presence of high 
glucose level might be a potential reason. Leptin activates 
proopiomelanocortin (POMC) neuron through the stim-
ulation of the janus kinase 2-phosphoinositide 3-kinase 
pathway in POMC neuron and the inhibition of gamma-
aminobutyric acid (GABA) release to POMC neuron in 
neuropeptide Y/agouti-related peptide neuron [37, 38]. 
Recent basic study found GABAergic synapses to POMC 
neurons differentially responded to leptin at different 
levels of glucose [39]. We found in diabetic subjects that 
reduced HRV was significantly association of with dura-
tion of diabetes, even though it was not significantly 
associated with HbA1c level.
Second, the presence of neuropathy may explain a dif-
ference in diabetic patients. Some previous studies have 
addressed the association between leptin and diabetic 
neuropathy with controversial results. Serum leptin level 
tended to be associated with sensory conduction veloc-
ity [40] in diabetic patients, while another study did not 
find any relationship [41]. In our hand, plasma leptin and 
HRV were not significantly different between diabetic 
patients with and without neuropathy. Interestingly, a 
significant association of leptin with HRV was seen in 
patients with, but not those without neuropathy. On the 
other hand, a recent study observed a decrease in HRV 
even in individuals with newly detected diabetes as well 
as those with impaired glucose tolerance [42]. Thus, the 
presence of neuropathy may not sufficiently explain why 
leptin is significantly associated with HRV only in dia-
betic patients.
Third, other comorbidities differentially distributed in 
the present two groups, such as hypertension, eGFR, and 
adiposity, may influence and modulate HRV parameters [4, 
43–45]. Indeed, a study in healthy subjects showed associ-
ation of leptin with HRV is dependent on BMI levels [33]. 
Thus, significantly higher BMI level in diabetic patients 
(26.1  kg/m2) than in non-diabetic patients (23.3  kg/m2) 
might contribute to inconsistent relation of leptin with 
HRV in our study. Several studies have shown that cardiac 
autonomic function is impaired in patients with cardiovas-
cular diseases [5, 6, 46]. However, the association between 
leptin and HRV was similar even after adjusting for previ-
ous CVD events, and the association remained similar in 
diabetic patients without previous CVD events.
sOb‑R and autonomic function
In this study, we also examined for the first time the asso-
ciation of plasma sOb-R with HRV. Although, plasma 
sOb-R tended to be inversely associated with adiposity, 
it was not significantly associated with any HRV param-
eters in our diabetic and non-diabetic patients.
Limitations
Our study design was cross-sectional, thus, even though 
relationships were explored in predictive terms, the 
results cannot be interpreted for any causal relationships. 
Longitudinal follow-up examinations of this cohort will 
clarify the role of leptin in autonomic dysfunction in 
patients with and without diabetes.
Conclusions
Our results showed that hyperleptinemia is associated 
with cardiac autonomic dysfunction in patients with dia-
betes, with the relationship independent of the accumu-
lation of visceral fat.
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